The DCGI is inclined to clear the Moderna vaccine soon as the government eyes a big vaccination target to prevent a third wave of COVID, news reports said
Pharmaceutical company Cipla filed an application on Monday with the Drugs Controller General of India (DCGI) to import and sell Moderna’s COVID-19 vaccine in India.
The DCGI is likely to grant permission to import the vaccine today itself, sources told CNBC-TV18.
Cipla told CNBC-TV18 that there have been no confirmatory or final agreements on vaccine imports as yet. They are seeking clarity and guidance on factors such as pricing, quantity, and indemnity clause. They have logistics such as distribution, storage of imported vaccines in place.
The DCGI is inclined to clear the Moderna vaccine soon as the government eyes a big vaccination target to prevent a third wave of COVID, news reports said.
Also Read: 13-Year-Old Disabled Child Shown “Vaccinated” On Madhya Pradesh’s Day Of Record Jabs
Cipla, in its application, referred to a decision of the government that said if a vaccine is approved for emergency use in any other country, it can be granted marketing authorization without a bridging trial.
Moderna’s method to protect against Covid-19 relies on messenger RNA (mRNA) to program cells to generate immunity to the coronavirus. This vaccine along with Pfizer are viewed as a preferred choice among wealthy countries, analysts said, based on clinical trial data showing they were more than 90% effective at preventing symptomatic coronavirus
Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
